We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Wants More Data Before Approving New Thalomid Indication
FDA Wants More Data Before Approving New Thalomid Indication
November 15, 2005
The FDA wants additional information from Celgene before it approves the firm’s leprosy drug Thalomid as a treatment for blood cancer.